中金辐照股份有限公司 关于中国黄金集团财务有限公司 风险持续评估报告 法定代表人：王赫 机构地址：北京市东城区安定门外大街9号一层 金融许可证机构编码：L0211H211000001 统一社会信用代码：91110000339854814H 财务公司在业务上接受国家金融监督管理总局及人民 银行的指导、监督和考核。按金融监管与公司治理要求，财 务公司设立了股东会、董事会、监事会和高级管理层。 经国家金融监督管理总局批准，并经北京市市场监督管 理局登记，目前财务公司经营范围为以下本外币业务： 根据《深圳证券交易所上市公司自律监管指引第 7 号 ——交易与关联交易》要求，中金辐照股份有限公司（简称 "中金辐照"或"公司"）通过查验中国黄金集团财务有限 公司（以下简称"财务公司"）《金融许可证》《营业执照》 等证件资料，审阅其2023年财务报告，对财务公司的经营资 质、内部控制建设、业务和风险状况及经营情况进行了评估， 具体情况报告如下： 一、中国黄金集团财务有限公司简介 财务公司是由中国黄金集团有限公司和中金黄金股份 有限公司共同出资设立的非银行金融机构，注册资本金10亿 元，中国黄金集团有限公司持股51%，注册地址 ...

中金辐照股份有限公司 2023 年度独立董事述职报告 述职人：赵永富 本人作为中金辐照股份有限公司（以下简称"公司"） 第三届董事会独立董事，严格按照《中华人民共和国公司法》 《中华人民共和国证券法》《上市公司独立董事管理办法》 等相关法律法规、规范性文件以及《公司章程》《独立董事 工作制度》等相关规定和要求，本着对全体股东负责的态度， 勤勉、忠实地履行独立董事职责，发挥独立董事的专业优势 和独立作用，努力维护并有效保障了公司全体股东，尤其是 中小股东的合法权益。现将本人 2023 年的工作情况报告如 下： 一、2023 年出席董事会和股东大会的情况 2.在 2023 年 8 月 25 日召开的公司第三届董事会第二十 九次会议上，本人对控股股东及其他关联方占用公司资金和 公司对外担保情况、公司 2023 年半年度募集资金存放与使 用情况、中国黄金集团财务有限公司的风险持续评估报告、 董事会换届选举暨提名第四届董事会非独立董事候选人、董 事会换届选举暨提名第四届董事会独立董事候选人等事项 发表了独立意见。 三、专门委员会的工作情况 本人作为公司第三届董事会薪酬与考核委员会主任委 员，按照公司《独立董事工作制度》 ...

证券代码：300962 证券简称：中金辐照 公告编号：2024-037 中金辐照股份有限公司 关于与中国黄金集团财务有限公司 续签《金融服务协议》暨关联交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 中金辐股份有限公司（以下简称"公司"）于 2024 年 4 月 26 日 召开第四届董事会第七次会议、第四届监事会第四次会议，审议通过 了《公司关于与中国黄金集团财务有限公司续签<金融服务协议>暨关 联交易的议案》，关联董事郑强国、朱然、梅治福、张冬波、陈强已 回避表决。公司独立董事专门会议已审议通过该议案并同意将其提交 董事会审议。本议案尚需提交公司 2023 年年度股东大会审议。 一、交易概述 公司与财务公司于 2021 年签订了 《金融服务协议》、2022 年 签订了 《<金融服务协议>之补充协议》 ，在《金融服务协议》有效 期内，甲方在乙方结算账户上各类存款每日余额(含累计结算利息) 合计不超过人民币 5 亿元；甲乙双方约定可循环使用的综合授信额 度不超过人民币 5 亿元 。上述事项的具体内容请详见公司于 2021 年 6 月 28 日和 20 ...

证券代码：300962 证券简称：中金辐照 公告编号：2024-021 中金辐照股份有限公司 关于使用闲置募集资金进行现金管理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 中金辐照股份有限公司(以下简称"公司")于 2024 年 4 月 26 日召 开第四届董事会第七次会议、第四届监事会第四次会议，审议通过了 《关于使用闲置募集资金进行现金管理的议案》，上述议案尚需提交公司 股东大会审议。 一、募集资金基本情况概述 经中国证券监督管理委员会《关于同意中金辐照股份有限公司首次 公开发行股票注册的批复》(证监许可〔2021〕249 号)同意注册，公司 于 2021 年 4 月 9 日公开发行人民币普通股 66,000,500.00 股，每股面值 人民币 1.00 元，每股发行价格为人民币 3.40 元，共计募集资金人民币 224,401,700.00 元，扣除承销费和发行费用后募集资金净额为人民币 199,498,991.54 元。 为规范募集资金管理和使用，保护投资者权益，公司设立了募集资 金专项账户，对募集资金专户存储。募集资金到账后，已全部存放于募 ...

关于 2023 年度募集资金存放与使用情况的专项报告 中金辐照股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上 市公司募集资金管理和使用的监管要求》《深圳证券交易所上市公司 自律监管指引第 2 号——创业板上市公司规范运作》以及《深圳证券 交易所创业板上市公司自律监管指南第 2 号——公告格式》等有关规 定，中金辐照股份有限公司（以下简称"公司"）董事会编制了 2023 年度募集资金存放与实际使用情况的专项报告，说明如下： 一、募集资金基本情况 证券代码：300962 证券简称：中金辐照 公告编号：2024-023 （一）实际募集资金金额、资金到账情况 经中国证券监督管理委员会《关于同意中金辐照股份有限公司首 次公开发行股票注册的批复》(证监许可〔2021〕249 号)同意注册， 公司于 2021 年 4 月 9 日公开发行人民币普通股 66,000,500.00 股， 每股面值人民币 1.00 元，每股发行价格为人民币 3.40 元，共计募集 资金人民币 224,401,700.00 ...

中金辐照股份有限公司 2024 年度财务预算方案 一、预算编制说明 本预算方案遵循谨慎性原则，在公司中长期发展战略框 架内，综合 2024 年宏观经济预期与公司经营发展等因素， 在公司预算基础上，按合并报表口径进行编制。 二、预算编制的基本假设 1.公司所遵循的国家和地方的现行有关法律、法规和制 度无重大变化； 2.公司主要经营所在地及业务涉及地区的社会经济环境 无重大变化； 3.现行主要税率、汇率、银行贷款利率不发生重大变化。 4.公司所处行业形势、市场需求无重大变化。 5.无其他不可抗拒力及不可预见因素造成的重大不利影 响。 三、主要预算指标 收入目标：2024 年实现营业收入 34,222 万元。 利润目标：2024 年实现利润总额 13,500 万元。 四、预算执行的保障和监督措施 公司 2024 年将围绕公司经营战略和全年预算目标，做 好指标的分解和责任落实，加强对预算执行情况的监控，建 立定期分析机制，加大协调、调度的频次及密度，及时发现 和解决问题。进一步完善绩效考核办法，提高各经营主体的 积极性，切实保障预算目标的实现。本方案将提交公司 2023 年度股东大会审议。 五、特别提示 公司 202 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥83,621,422.72, representing a 4.09% increase compared to ¥80,334,442.58 in the same period last year[5] - The net profit attributable to shareholders for Q1 2024 was ¥29,836,447.36, a 1.82% increase from ¥29,302,851.57 in the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥29,131,321.56, up 2.06% from ¥28,542,332.09 year-on-year[5] - The total operating revenue for Q1 2024 was CNY 83,621,422.72, an increase of 2.4% compared to CNY 80,334,442.58 in the previous period[14] - Net profit attributable to the parent company increased to CNY 370,805,652.85, compared to CNY 340,969,205.49 in the previous period, representing an increase of 8.8%[13] - The net profit for Q1 2024 was CNY 30,804,107.18, a slight increase from CNY 30,768,208.98 in Q1 2023, representing a growth of 0.12%[15] - The total comprehensive income for Q1 2024 was CNY 30,804,107.18, slightly higher than CNY 30,768,208.98 in Q1 2023, reflecting a growth of 0.12%[15] Cash Flow - The net cash flow from operating activities for Q1 2024 was ¥42,380,496.25, reflecting a 9.13% increase from ¥38,835,242.83 in the same period last year[5] - Cash flow from operating activities for Q1 2024 was CNY 42,380,496.25, up from CNY 38,835,242.83 in Q1 2023, reflecting a growth of 6.3%[17] - The net cash flow from investing activities for Q1 2024 was -CNY 32,968,882.54, compared to -CNY 7,031,611.65 in Q1 2023, indicating an increase in cash outflow due to investments[17] - The total cash outflow from financing activities in Q1 2024 was CNY 462,028.46, down from CNY 4,756,348.09 in Q1 2023, indicating a significant reduction in cash outflow[18] Assets and Liabilities - The total assets at the end of Q1 2024 were ¥1,126,836,916.44, which is a 2.23% increase from ¥1,102,213,048.58 at the end of the previous year[5] - Total assets reached CNY 1,126,836,916.44, up from CNY 1,102,213,048.58, reflecting a growth of 2.2%[13] - Total liabilities decreased to CNY 145,600,851.44 from CNY 151,781,090.76, a reduction of 4.1%[13] Shareholder Equity - The equity attributable to shareholders at the end of Q1 2024 was ¥945,993,062.24, marking a 3.26% increase from ¥916,156,614.88 at the end of the previous year[5] - The company’s total equity attributable to shareholders increased to CNY 945,993,062.24 from CNY 916,156,614.88, an increase of 3.3%[13] Earnings Per Share - The basic earnings per share for Q1 2024 were ¥0.1130, up 1.80% from ¥0.1110 in the same period last year[5] - The diluted earnings per share for Q1 2024 were also ¥0.1130, reflecting a 1.80% increase compared to ¥0.1110 in the previous year[5] - Basic and diluted earnings per share for Q1 2024 were both CNY 0.1130, up from CNY 0.1110 in Q1 2023, showing an increase of 1.8%[15] Operating Costs and Expenses - Total operating costs for Q1 2024 amounted to CNY 48,064,108.10, up from CNY 45,035,844.36, reflecting a growth of 6.7%[14] - The company reported a research and development expense of CNY 5,430,514.21, which is an increase of 13.8% from CNY 4,772,873.34 in the previous period[14] Other Financial Metrics - The weighted average return on equity for Q1 2024 was 3.20%, a slight decrease of 0.05% from 3.25% in the same period last year[5] - The company received government subsidies amounting to ¥888,977.25 during the quarter, contributing positively to the financial results[6] - Accounts receivable rose to CNY 33,065,113.78 from CNY 24,859,844.09, indicating a significant increase of 32.8%[12] - Inventory increased to CNY 934,344.04 from CNY 497,409.37, marking an increase of 87.7%[12] - The operating profit for Q1 2024 was CNY 36,229,770.47, compared to CNY 35,726,939.73 in the same period last year, indicating an increase of 1.4%[15] - The company reported a decrease in minority shareholders' profit to CNY 967,659.82 in Q1 2024 from CNY 1,465,357.41 in Q1 2023, a decline of 33.9%[15]

Financial Performance - The company's operating revenue for 2023 was CNY 344,754,344.76, representing a 2.26% increase compared to CNY 337,129,684.48 in 2022[19]. - The net profit attributable to shareholders for 2023 was CNY 108,077,920.58, a slight increase of 0.33% from CNY 107,726,331.01 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was CNY 102,423,177.89, which is a decrease of 2.68% compared to CNY 105,243,913.31 in 2022[19]. - The net cash flow from operating activities for 2023 was CNY 188,380,816.34, up by 1.59% from CNY 185,428,812.96 in 2022[19]. - The total assets at the end of 2023 amounted to CNY 1,102,213,048.58, reflecting a 3.06% increase from CNY 1,069,442,193.97 at the end of 2022[19]. - The net assets attributable to shareholders increased by 3.25% to CNY 916,156,614.88 at the end of 2023, compared to CNY 887,279,263.40 at the end of 2022[19]. - The basic earnings per share for 2023 was CNY 0.4094, a 0.32% increase from CNY 0.4081 in 2022[19]. - The company reported a quarterly revenue breakdown, with the highest revenue in Q2 at CNY 89,238,524.42[21]. - The company reported a net profit of 5,654,742.69 yuan from non-recurring gains and losses in 2023, an increase from 2,482,417.70 yuan in 2022, reflecting a growth of approximately 128.0%[25]. - The gross profit margin for irradiation technology services was 64.52%, showing a decrease of 0.80% compared to the previous year[77]. Dividend Distribution - The company plans to distribute a cash dividend of CNY 2.90 per 10 shares to all shareholders, based on a total of 264,001,897 shares[4]. - The company has implemented a cash dividend distribution of CNY 3.00 per 10 shares, totaling CNY 79.20 million to shareholders[67]. - The total distributable profit for the year is 77,027,621.53 CNY, with the cash dividend accounting for 100% of the total profit distribution[182]. - No stock bonus or share capital increase is proposed for the reporting period[182]. Market and Industry Insights - The company primarily engages in irradiation technology services, which are the main source of revenue and profit, focusing on sterilization services for medical products, food, pharmaceuticals, and packaging materials[33]. - The irradiation technology service market is expanding, with significant growth in the application of radiation processing in material modification, food irradiation, and medical sterilization[32]. - The company is part of the strategic emerging industry supported by the state, with continuous development and expansion of application areas in radiation processing technology[32]. - The irradiation technology industry in China is entering a rapid expansion phase, with increasing market demand driving the enhancement of irradiation device design capabilities[31]. - The global irradiation technology market is growing, with developed countries leading in the application and commercialization of irradiation technology[30]. Research and Development - The company launched 44 new technology research projects and obtained 30 new patents in 2023, enhancing its core competitive capabilities[71]. - Research and development (R&D) investment amounted to CNY 26,565,837.58, representing 7.71% of total revenue, up from 7.64% in 2022[87]. - The number of R&D personnel increased to 140, a rise of 1.45% from 138 in 2022, with a slight decrease in the proportion of R&D personnel to total employees[87]. - The company has initiated 44 new technology research projects in 2023, resulting in 30 new patents, including innovations in irradiation dose calibration and monitoring systems[58]. Operational Efficiency - The company has established a procurement system for cobalt sources, essential for irradiation services, requiring various regulatory approvals[47]. - The company has adopted a centralized management model for cobalt source procurement, which helps reduce costs and improve resource allocation efficiency[65]. - The company optimized the utilization of cobalt sources, improving efficiency by 2%, which contributed to reduced production costs[86]. - The company aims to enhance the automation level of its warehouse management system, improving production management efficiency[86]. Governance and Compliance - The company is committed to enhancing its governance and compliance, achieving an A-level rating in information disclosure for two consecutive years[72]. - The company emphasizes independent operations and governance, ensuring no interference from controlling shareholders in decision-making[125]. - The company has established independent decision-making and supervisory bodies, including the shareholders' meeting, board of directors, and supervisory board[137]. - The company has complied with information disclosure obligations, ensuring that all investors have equal access to relevant information[130]. Strategic Planning - The company is actively expanding its market presence and enhancing competitiveness through strategic investments and technology applications, aiming for high-quality development[56]. - The company plans to optimize its investment layout and increase market research efforts to align with national strategic goals[113]. - The company will focus on expanding its market presence in new fields of irradiation technology and disinfection supply services to boost performance[116]. - The company is committed to improving safety management and compliance to mitigate operational risks associated with nuclear technology[115]. Employee and Management Structure - The total number of employees at the end of the reporting period was 603, with 549 from major subsidiaries and 54 from the parent company[178]. - The company implemented a salary management system based on performance and capability, with a focus on efficiency and fairness[179]. - The total pre-tax remuneration for directors, supervisors, and senior management in 2023 amounted to 6.5953 million yuan, which includes basic salary, bonuses, and various insurance fees[163]. - The company has a performance-based salary structure for senior management, with performance pay determined by annual operational and financial goals[163]. Environmental and Social Responsibility - The company actively disclosed its ESG report for 2020-2022, showcasing its governance, environmental protection, and social responsibility efforts[192]. - The company participated in poverty alleviation and rural revitalization activities, including fundraising and support for impoverished children[193]. - The company is committed to ecological civilization and environmental protection, continuously improving its environmental management system[192]. - The company has implemented measures to reduce carbon emissions, although specific results were not disclosed[192].

2023 年度的审计机构。 二、审计委员会对会计师事务所监督情况 根据公司《董事会审计委员会议事规则》等有关规定， 审计委员会对会计师事务所履行监督职责的情况如下： 中金辐照股份有限公司董事会审计委员会 对会计师事务所履行监督职责情况报告 根据《中华人民共和国公司法》《中华人民共和国证券 法》《上市公司治理准则》《国有企业、上市公司选聘会计 师事务所管理办法》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》等规定和要求，中 金辐照股份有限公司（以下简称"公司"）董事会审计委员 会本着勤勉尽责的原则，恪尽职守，认真履职。现将公司董 事会审计委员会对会计师事务所履行监督职责的情况汇报 如下： 一、2023 年年审会计师事务所基本情况 （一）会计师事务所基本情况 中兴华会计师事务所（特殊普通合伙）（以下简称"中 兴华"）成立于 1993 年，2013 年 11 月进行合伙制转制。注 册地址为北京市丰台区丽泽路 20 号院 1 号楼南楼 20 层。首 席合伙人为李尊农先生。截至 2023 年 12 月 31 日，中兴华 拥有合伙人 189 名、注册会计师 969 名、签署过证券服务业 务审 ...

审计报告书 中金辐照股份有限公司 2023年度合并及母公司财务报表 中兴华会计师事务所(特殊普通合伙) ZHONGXINGHUA CERTIFIED PUBLIC ACCOUNTANTS LLP 地址：北京市丰台区丽泽路 20号丽泽 SOHO Ｂ座 20层 邮编：100073 电话：(010) 51423818 传真：(010) 51423816 一、 审计意见 我们审计了中金辐照股份有限公司（以下简称中金辐照）财务报表，包括 2023 年 12 月 31 日的合并及母公司资产负债表，2023 年度的合并及母公司利润 表、合并及母公司现金流量表、合并及母公司股东权益变动表以及相关财务报表 附注。 目 录 2. 中兴华会计师事务所（特殊普通合伙）执业证书复印件 3. 注册会计师执业证书复印件 中 兴 华 会 计 师 事 务 所 （ 特 殊 普 通 合 伙 ） Z H O N G X I N G H U A C E R T I F I E D P U B L I C A C C O U N T A N T S L L P 地址（ l o c a t i o n ）：北京市丰台区丽泽路 2 0 号 丽 泽 S O ...